Jefferies & Company commented on Incyte INCY in a report released yesterday. In the report, Jefferies & Company was positive in its assessment of the company.
Jefferies & Company writes, "INCY released new
detail from the COMFORT-2 European study of ruxolitinib in myelofibrosis. On the primary
endpoint, 28.5% of MF patients treated with ruxolitiniib experienced a 35+% reduction in
spleen size at week 48 compared to 0% in the arm receiving best available therapy (BAT,
p<0.0001). These rates are lower than observed in COMFORT-1 (41% at week 24), but we
do not believe that the efficacy data are materially different, and in fact, we learned that the
median spleen size reduction in both trials is very close (33% for COMFORT-1 vs. 29% for
COMFORT-2). We remain positive on ruxolitinib's efficacy profile."
Jefferies & Company currently has a Buy rating on Incyte. Shares of the company closed at 16.90 on Monday, up $0.39 from the opening bell.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in